Maharashtra Herald

Rheumatoid Arthritis Market is Expected to Grow at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Estimates DelveInsight

 Breaking News
  • No posts were found

Rheumatoid Arthritis Market is Expected to Grow at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Estimates DelveInsight

January 19
20:49 2023
Rheumatoid Arthritis Market is Expected to Grow at a Minimal CAGR of 1.9% During the Study Period (2019-2032), Estimates DelveInsight
Rheumatoid Arthritis Market

DelveInsight’s Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the 7MM [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

 

Key Takeaways from the Rheumatoid Arthritis Market Report

  • As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4.7 million in 2021.
  • Leading rheumatoid arthritis companies such as Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others are developing novel rheumatoid arthritis drugs that can be available in the rheumatoid arthritis market in the coming years.
  • The promising rheumatoid arthritis therapies in the pipeline include Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others.
  • In June 2022, Cyxone received a response from a Type B Pre-IND meeting with the US FDA. The response from the FDA facilitates Cyxone to continue planning the Phase IIb study with Rabeximod in RA.
  • In December 2021, Taisho Pharmaceuticals presented the interim results from a 24-week administration in Phase II/III clinical trial (OHZORA study) of ozoralizumab in adult patients with RA at the annual meeting of the Japanese Society for Clinical Rheumatology and Related Research.

 

Discover which therapies are expected to grab the major rheumatoid arthritis market share @ Rheumatoid Arthritis Market Report

 

Rheumatoid Arthritis Overview

Rheumatoid arthritis is a type of autoimmune disease. It happens when our immune system, which is supposed to defend us, malfunctions and starts attacking our own tissues. It causes inflammation in the joint lining (the synovium). As a result, joints may become red, warm, swollen, and painful, which are all symptoms of rheumatoid arthritis. The precise causes of rheumatoid arthritis are still unknown.

Because the early signs and symptoms of rheumatoid arthritis are similar to those of many other diseases, it can be difficult to detect in its early stages. There is no single blood test or physical finding that can confirm the diagnosis of rheumatoid arthritis.

There is no known cure for rheumatoid arthritis. However, clinical trials of rheumatoid arthritis show that remission of symptoms is more common when rheumatoid arthritis treatment with disease-modifying antirheumatic medicines begins early (DMARDs).

 

Rheumatoid Arthritis Epidemiology Segmentation

DelveInsight estimates that there were approximately 4.7 million prevalent cases of rheumatoid arthritis in the 7MM in 2021.

Among the EU4 and the UK countries, Germany accounted for the highest number of rheumatoid arthritis cases, whereas France accounted for the lowest cases in 2021

The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalent Cases
  • Total Diagnosed Prevalent Cases
  • Gender-specific Prevalent Cases
  • Age-specific Prevalent Cases
  • Severity-specific Prevalent Cases
  • Patients on Targeted Therapies
  • Line-Wise Treated Cases

 

Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights

 

Rheumatoid Arthritis Treatment Market

Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression.

Moreover, disease-modifying antirheumatic drugs (DMARDs) are used to target inflammation and prevent further joint damage and disease progression. DMARDs are a class of drugs that have been shown to affect the underlying cause of rheumatoid arthritis by reducing immune system overactivity, thereby alleviating pain, swelling, and stiffness and preventing joint changes. DMARDs can be prescribed singly or in combination as an initial part of treatment.

Methotrexate is the first-line DMARD agent for the majority of rheumatoid arthritis patients. It has a relatively quick onset of action at therapeutic doses (6-8 weeks), good efficacy, a low toxicity profile, is easy to administer, and is relatively inexpensive.

 

To know more about rheumatoid arthritis guidelines, visit @ Rheumatoid Arthritis Management

 

Rheumatoid Arthritis Pipeline Therapies and Key Companies

  • Artlegia (Olokizumab): R-Pharm
  • TS-152 (Ozoralizumab): Taisho Pharmaceuticals
  • Otilimab (GSK3196165/MOR103): GlaxoSmithKline
  • ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics
  • Branebrutinib: Bristol Myers Squibb
  • LY3462817: Eli Lilly and Company
  • TAS5315: Taiho Pharmaceutical
  • Rabeximod (Rob 803): Cyxone
  • GS-5718: Gilead Sciences
  • KPL-404: Kiniksa Pharmaceuticals
  • MBS2320: Istesso
  • AMT-101: Applied Molecular Transport
  • Dazodalibep (HZN-4920): Horizon Therapeutics
  • Cevidoplenib (SKI-O-703): Genosco/Oscotec
  • HB-AdMSCs: Hope Biosciences
  • ABX464: Abivax
  • MPC-300-IV: Mesoblast
  • PF-06650833: Pfizer
  • JTE 051: Akros Pharma/Japan Tobacco
  • Dekavil (F8IL10): Pfizer/Philogen
  • ABBV-154: AbbVie
  • PF-06651600 (Ritlecitinib): Pfizer
  • AP1189: SynAct Pharma

 

Learn more about the FDA-approved drugs for rheumatoid arthritis @ Drugs for Rheumatoid Arthritis Treatment

 

Rheumatoid Arthritis Market Dynamics

The dynamics of the rheumatoid arthritis market is anticipated to change in the future due to the increasing awareness and expected increase in investment in the R&D activities by the leading companies working in the rheumatoid arthritis market space. Moreover, current therapies, such as biological DMARDs, have shown promising results in treating rheumatoid arthritis patients, and market penetration is expected to increase in the future, driving rheumatoid arthritis market growth.

Furthermore, there is still a high demand for therapies with a similar efficacy profile to current therapies but a better safety profile and a more patient-friendly RoA. Oral classes, such as JAKi and the upcoming BTKi, are expected to contribute to the rheumatoid arthritis market growth due to patient-friendly RoA.

However, several factors are likely to hamper the rheumatoid arthritis market growth. The rheumatoid arthritis market is highly competitive, and new entrants are expected to face some resistance and low uptake because anti-TNFs currently dominate the rheumatoid arthritis market, and the entry of biosimilars will pose significant challenges to new and upcoming treatment options in the rheumatoid arthritis market.

In addition, the entry of biosimilars has already begun in the US and EU (i.e., Remicade biosimilars), and as a result, sales value has started to decline. The impact will be more pronounced when biosimilars/ generics of some blockbuster drugs, such as Humira (i.e., 2023 in the US), Xeljanz (i.e., 2025 in the US), will enter the rheumatoid arthritis market, and this will significantly impact the growth of the rheumatoid arthritis market.

 

 

Scope of the Rheumatoid Arthritis Market Report

  • Therapeutic Assessment: Rheumatoid Arthritis current marketed and emerging therapies
  • Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Rheumatoid Arthritis Market Access and Reimbursement

 

Discover more about rheumatoid arthritis drugs in development @ Rheumatoid Arthritis Clinical Trials

 

Table of Contents

1.

Rheumatoid Arthritis Market Key Insights

2.

Rheumatoid Arthritis Market Report Introduction

3.

Rheumatoid Arthritis Market Overview at a Glance

4.

Rheumatoid Arthritis Market Executive Summary

5.

Rheumatoid Arthritis Key Events

6.

Rheumatoid Arthritis Epidemiology and Market Methodology

7.

Rheumatoid Arthritis Background and Overview

8.

Rheumatoid Arthritis Treatment and Management

9.

Rheumatoid Arthritis Epidemiology and Patient Population

9.1

Key Finding

9.2

Assumptions and Rationale

9.3

Total Prevalent Population of Rheumatoid Arthritis in the 7MM

9.4

United States

9.5

EU4 and the UK

9.6

Japan

10

Rheumatoid Arthritis Patient Journey

11.

Key Endpoints in Rheumatoid Arthritis Clinical Trials

12.

Rheumatoid Arthritis Marketed Drugs

13.

Rheumatoid Arthritis Emerging Drugs

14.

Seven Major Rheumatoid Arthritis Market Analysis

14.1

Key Finding

14.2

Rheumatoid Arthritis Market Outlook

14.3

Attribute Analysis

14.4

Key Market Forecast Assumptions

14.5

Total Market Size of Rheumatoid Arthritis in the 7MM

14.6

United States

14.7

EU4 and the UK

14.8

Japan

15.

Unmet Needs

16.

SWOT Analysis

17.

Rheumatoid Arthritis Market Access and Reimbursement

18.

Appendix

19

DelveInsight Capabilities

20.

Disclaimer

21.

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting